Does Trazodone Help With Nerve Pain?

Trazodone is not a proven treatment for nerve pain, and the clinical evidence backing its use for neuropathic conditions remains limited and inconsistent. A handful of small human trials and several animal studies suggest the drug has some capacity to modify pain signals, particularly when paired with medications like gabapentin, but no large randomized trial has established it as a reliable standalone option. The picture is complicated by trazodone’s unusual pharmacology, which touches on both serotonin pathways and opioid receptors in ways researchers are still working to understand.

How Trazodone Might Influence Pain Signals

Trazodone was designed as an antidepressant and is classified as a serotonin antagonist and reuptake inhibitor. Its relationship to pain is a side story that emerged from its complex receptor profile. In mouse studies, the drug’s pain-relieving activity appears to work primarily through two routes: mu-opioid receptor subtypes and serotonin receptors. When researchers blocked serotonin receptors with an antagonist, trazodone’s analgesic effect dropped significantly, confirming serotonin’s role. Blocking adrenergic receptors, by contrast, made no difference.¹

What makes trazodone unusual among antidepressants is how dramatically its effects change depending on the dose. Pharmacokinetic modeling has shown that low doses, around 50 mg daily, are enough to block the receptors responsible for its sedating and sleep-promoting effects. Higher doses are needed for antidepressant activity, which requires greater serotonin receptor engagement.² This dose-dependent behavior matters for pain because it means the drug may be doing very different things at the low doses typically prescribed off-label for sleep compared to the higher doses used in depression or pain research.

What Animal Studies Show

Before trazodone reaches a human pain trial, researchers test it in rodent models of neuropathic pain, and the results here are more encouraging than the human data. In a rat model of nerve injury, trazodone showed clear dose-dependent pain relief, and this effect persisted even when the serotonin-producing neurons in the brainstem were chemically destroyed, suggesting the drug’s analgesic pathway does not rely solely on the brain’s own serotonin supply.³

A separate rat study using a partial sciatic nerve ligation model found that trazodone at two dose levels reduced cold-stimulus pain significantly, though it was less effective against heat-related and mechanical pain compared to a standard reference drug.⁴ So even in animals, trazodone’s pain relief is partial and uneven. It seems to work better against some types of nerve pain than others.

The most intriguing preclinical finding involves combining trazodone with gabapentin. Using isobolographic analysis, researchers demonstrated that the two drugs act synergistically in rodent neuropathic pain models. Doses of trazodone and gabapentin that individually had no measurable effect on pain produced significant relief when given together.⁵ This synergy finding is what drives much of the current clinical interest in trazodone for neuropathic pain, as the hope is that combining a low dose of trazodone with gabapentin could boost pain relief without proportionally increasing side effects.

Clinical Trials in Diabetic Neuropathy

Diabetic neuropathy is the nerve pain condition where trazodone has received the most structured clinical testing, but the results have been underwhelming by conventional statistical standards. A randomized controlled pilot study added low-dose trazodone (either 30 mg or 60 mg daily) or placebo on top of gabapentin in patients with painful diabetic neuropathy. After eight weeks, none of the trazodone groups showed a statistically significant reduction in average pain intensity compared to placebo. There was a numerical trend favoring the 30 mg group, and roughly 63% of patients in that group achieved at least a 50% reduction in pain, compared to about 46% on placebo. The 30 mg group also showed a statistically significant improvement in how much pain interfered with daily activities.⁶

A follow-up dose-finding study tested a fixed-dose combination of trazodone and gabapentin at three dose levels against gabapentin alone and placebo. Again, after eight weeks, none of the combination groups reached statistical significance on the primary pain measure compared to placebo. The lowest dose combination did show a statistically significant difference at the six-week mark, however, and consistently performed better on secondary measures related to anxiety, depression, sleep, and quality of life.⁷

Two patterns emerge from these trials. First, the lowest trazodone dose outperformed higher doses in both studies, which is unusual and not fully explained. Second, while the primary pain endpoints missed significance, the secondary measures around functional impact and quality of life consistently favored trazodone. These are pilot-scale studies with modest sample sizes, so they were not powered to detect small-to-moderate effects. Researchers interpret them as signals worth pursuing in larger confirmatory trials, not as evidence that trazodone works or does not work for diabetic nerve pain.

Spinal Cord Injury and Deafferentation Pain

Not all nerve pain is the same, and trazodone’s performance varies depending on the condition. In one of the earliest randomized, placebo-controlled trials, trazodone at 150 mg daily was tested against placebo in patients with dysesthetic pain from traumatic spinal cord injury. The result was clearly negative: there were no significant differences in any pain measure between the trazodone and placebo groups. Making matters worse, significantly more patients on trazodone dropped out of the study because of side effects.⁸

Deafferentation pain, the persistent pain that follows damage to or disconnection of nerve fibers, tells a different story. In two separate studies comparing trazodone head-to-head with amitriptyline (a tricyclic antidepressant with well-established use in neuropathic pain), the analgesic effects of the two drugs were judged to be similar.⁹¹⁰ These were small trials, but the finding matters because amitriptyline is one of the standard options for nerve pain. Matching it, even in limited data, suggests trazodone has genuine analgesic activity in some pain subtypes.

A review of antidepressants for neuropathic pain summed up the situation plainly: studies using trazodone in neuropathic pain have yielded conflicting results, with some reports describing usefulness in diabetic neuropathy at doses as low as 50 to 100 mg daily, while a placebo-controlled trial for burning mouth pain found no benefit.¹¹ The inconsistency likely reflects both the heterogeneity of nerve pain conditions and the small scale of most studies.

The Fibromyalgia Angle

Fibromyalgia is not neuropathic pain in the traditional sense, but it involves abnormal pain processing in the central nervous system and shares enough features with nerve pain that researchers have studied trazodone in this population too. The findings reveal a consistent and somewhat puzzling pattern: trazodone improves how much pain disrupts daily life without clearly reducing pain intensity itself.

In a 12-week open-label study of fibromyalgia patients, trazodone did not markedly improve pain intensity scores but had a significant effect on how much pain interfered with everyday activities.¹² A follow-up study took this further by first treating patients with trazodone alone for 12 weeks, then adding pregabalin for another 12 weeks. Trazodone alone again improved sleep, depression, and pain interference without directly reducing body pain. Adding pregabalin produced additional improvements, including a decrease in actual pain levels.¹³

This distinction between pain intensity and pain interference is important. It suggests trazodone may help people cope with pain, possibly by improving sleep and mood, rather than blocking the pain signal directly. For someone living with chronic pain, that functional improvement can matter as much as a change on a pain scale, but it is a different kind of benefit than what most people imagine when they ask whether a drug “helps with pain.”

Safety and Side Effects

One of the practical reasons trazodone keeps appearing in pain-management conversations is that its side-effect profile differs from the tricyclic antidepressants traditionally used for nerve pain. Tricyclics like amitriptyline are effective but carry a heavy burden of anticholinergic effects: dry mouth, constipation, urinary retention, blurred vision, and cognitive fog. In elderly patients particularly, trazodone produces far fewer of these problems. Drowsiness is the most commonly reported side effect, which can be reframed as a benefit when insomnia is part of the clinical picture.¹⁴

That does not mean trazodone is without risk. The side effects to watch for include:

Orthostatic hypotension: A drop in blood pressure upon standing, which can cause dizziness or fainting, especially in older adults.
Cardiac arrhythmias: Uncommon but documented, requiring monitoring in patients with pre-existing heart conditions.
Priapism: A rare but serious adverse effect occurring in roughly 1 in 6,000 male patients, involving a prolonged, painful erection that requires emergency treatment.
Excessive sedation: While often considered the main side effect, the drowsiness can be dose-limiting and impair daily functioning, particularly at the higher doses that pain research has sometimes explored.

The spinal cord injury trial discussed earlier underscored that side effects can be a real problem. In that study, patients randomized to trazodone at 150 mg daily were significantly more likely to drop out because of adverse effects than those on placebo.⁸ Tolerability appears better at the lower doses used in the more recent diabetic neuropathy trials, which is another reason the research has shifted toward low-dose combination approaches.

How Trazodone Compares to First-Line Options

Guidelines for neuropathic pain management generally recommend tricyclic antidepressants like amitriptyline and nortriptyline, serotonin-norepinephrine reuptake inhibitors (SNRIs) like duloxetine and venlafaxine, and anticonvulsants like gabapentin and pregabalin as first-line treatments. Trazodone does not appear in any major guideline as a recommended therapy for neuropathic pain. The evidence base is simply too thin and contradictory for that.

What the limited head-to-head data suggests is that trazodone can match amitriptyline’s pain relief in certain deafferentation pain conditions while producing fewer anticholinergic side effects.⁹¹⁴ For someone who cannot tolerate a tricyclic because of its side effects, trazodone might be a reasonable alternative to discuss with their doctor. But this is an extrapolation from very small studies, not a well-supported recommendation.

Duloxetine and venlafaxine, which inhibit reuptake of both serotonin and norepinephrine, have far stronger evidence for neuropathic pain. Trazodone’s serotonin reuptake blockade is actually weak and probably not clinically meaningful at typical doses, which is part of why it behaves so differently from SSRIs and SNRIs.¹¹ The norepinephrine component, which is central to how duloxetine works on descending pain-inhibitory pathways, is not a major feature of trazodone’s pharmacology at low doses.

The Sleep Connection

Insomnia is the most common reason trazodone is prescribed, and its use for sleep dwarfs its use for depression in many health systems. This matters for pain because sleep disruption and chronic pain have a bidirectional relationship: poor sleep worsens pain, and pain disrupts sleep, creating a cycle that is difficult to break. Trazodone’s ability to improve sleep at low doses, well below those studied in pain trials, may offer an indirect benefit to people with nerve pain even if the drug is not directly reducing pain signal transmission.²

The fibromyalgia studies reinforce this idea. In those trials, the pattern was consistent: sleep quality improved, pain interference improved, but raw pain intensity did not change much. The most plausible explanation is that better sleep and improved mood raise the threshold at which pain disrupts life, even if the pain signals themselves are unchanged. For a patient already taking gabapentin or pregabalin for nerve pain and still struggling with sleep, adding low-dose trazodone may address the insomnia component of their problem without requiring a separate sleeping pill.

Off-Label Prescribing Realities

Despite the thin evidence, trazodone is prescribed off-label for chronic pain conditions including diabetic neuropathy and fibromyalgia. A review of its off-label uses confirmed that chronic pain and diabetic neuropathy are among the recognized non-approved indications for the drug.¹⁵ This kind of off-label use is common in pain management, where the number of approved options is small relative to the number of patients who do not respond adequately to first-line treatments.

If your doctor has prescribed or suggested trazodone for nerve pain, it is worth understanding what the prescription is and is not based on. It is not based on strong trial evidence showing that trazodone reliably reduces neuropathic pain. It is based on a combination of preclinical findings, small clinical studies with suggestive but inconclusive results, its favorable side-effect profile compared to tricyclics, and its ability to improve sleep and reduce how much pain interferes with daily functioning. For some patients, especially those dealing with insomnia and mood issues alongside their nerve pain, that combination of modest benefits may add up to meaningful improvement. For others who are looking for a drug with strong evidence of direct pain relief, the current data does not support trazodone as a primary choice.

The research direction that looks most promising is the low-dose trazodone-gabapentin combination, building on the synergy demonstrated in animal models.⁵ The two diabetic neuropathy trials tested this concept in humans and found encouraging trends, particularly at the lowest dose combination, without reaching clear statistical significance on primary pain outcomes.⁷ Larger confirmatory trials are the next step, and a fixed-dose combination product is in development. Until those results arrive, trazodone’s place in nerve pain management remains a plausible idea with preliminary support rather than an established therapy.

1
PubMed. The antinociceptive effect of trazodone in mice is mediated through both mu-opioid and serotonergic mechanisms
2
PubMed. Evaluating the dose-dependent mechanism of action of trazodone by estimation of occupancies for different brain neurotransmitter targets
3
PubMed. Trazodone hydrochloride attenuates thermal hyperalgesia in a chronic constriction injury rat model
4
Brazilian Journal of Pharmaceutical Sciences. Alleviation of neuropathic pain by trazodone in rats
5
PLoS ONE. Synergistic interaction between trazodone and gabapentin in rodent models of neuropathic pain
6
PubMed Central. Efficacy and Safety of Low Doses of Trazodone in Patients Affected by Painful Diabetic Neuropathy and Treated with Gabapentin: A Randomized Controlled Pilot Study
7
PubMed Central. Efficacy and Safety of Trazodone and Gabapentin Fixed-Dose Combination in Patients Affected by Painful Diabetic Neuropathy: Randomized, Controlled, Dose-Finding Study
8
Pain. Trazodone hydrochloride in the treatment of dysesthetic pain in traumatic myelopathy: a randomized, double-blind, placebo-controlled study
9
PubMed. Trazodone for deafferentation pain. Comparison with amitriptyline
10
PubMed. Antidepressants for cancer pain and other painful syndromes with deafferentation component: comparison of amitriptyline and trazodone
11
Hong Kong Journal of Psychiatry. Antidepressants for the Treatment of Neuropathic Pain
12
PubMed Central. Trazodone for the treatment of fibromyalgia: an open-label, 12-week study
13
PubMed Central. Trazodone plus pregabalin combination in the treatment of fibromyalgia: a two-phase, 24-week, open-label uncontrolled study
14
PubMed. Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders
15
Expert Opinion on Pharmacotherapy. Off-label uses of trazodone: a review